slt

Kevin P. Smith

General Counsel & Executive Vice President, Business Development

Experience and Expertise

Kevin is a seasoned lawyer and compliance officer with more than 20 years' experience across the biotechnology, pharmaceutical, medical device, healthcare, intellectual property and high-technology sectors.

Kevin joined Sirtex as General Counsel & Chief Compliance Officer in 2018. In addition to ensuring global compliance with all laws, rules and regulations applicable to the company, he manages the legal functions including corporate governance, IP, contracts, employment and business development.

Before coming to Sirtex, Kevin was VP & Associate General Counsel at Flexion Therapeutics and also previously the General Counsel for the Danaher Life Sciences Platform, managing legal and compliance matters for the platform.  Before that, Kevin held several senior legal leadership positions within Novartis Pharmaceuticals in Basel and Cambridge, including as the General Counsel for the Novartis Molecular Diagnostics Unit.  Before moving in-house, Kevin worked for multinational law firms in New York, Silicon Valley and London.  

Kevin earned a Juris Doctorate, magna cum laude, from Albany Law School of Union University and a B.S. in Mechanical Engineering from Rensselaer Polytechnic Institute. A member of the California and New York State bars and a Massachusetts Registered In-House Counsel, Kevin is also a Registered Patent Attorney with the U.S. Patent and Trademark Office. 




slt
Kevin R. Smith
CEO

slt
Paul Andreassi
Executive Vice President of Global Quality Assurance

slt
Jesse Hansen
Global Head of Marketing

slt
Francis Jannot
Executive Vice President of International Sales

slt
Cathleen Lowndes
Chief Human Resources Officer

slt
Amy Pan
Chief Financial Officer

slt
Suki Shergill
Executive Vice President, Global Pricing & Market Access

slt
Kevin P. Smith
General Counsel & Executive Vice President, Business Development

slt
Grant Spindler
Global Head of Operations

slt
MaryLou Stroumbos
Executive Vice President, Regulatory Affairs

slt
Mark Turco
Global Chief Medical Officer & Executive Vice President of Research & Development



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Click here to view our Technical Bulletin.

Ok